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Theirmost remarkableﬁnding is the ability of very young infants (youn-
ger than 4 months), to mount a strong IgG3 response upon RSV infec-
tion even in the presence of high levels of maternal RSV-neutralizing
antibodies. In contrast, a rise in RSV glycoprotein-speciﬁc serum IgG1
and IgG2, and RSV-neutralizing antibodies following RSV infection was
only observed consistently in infants older than 7months, i.e.whenma-Human respiratory syncytial virus (RSV) is the most frequent cause
of lower respiratory tract infections in infants and young children
worldwide and also an important pathogen in elderly. Millions of pa-
tients get hospitalized and up to 200,000 children die each year due to
an RSV infection (Nair et al., 2010). Despite this burden and decades
of research there is neither a prophylactic vaccine nor a speciﬁc antiviral
therapy for RSV. Amajor obstacle for the development of an RSV vaccine
is the lack of a strong correlate of protection. High levels of RSV-neutral-
izing antibodies have been associated with less severe disease but this
association is not strong and sometimes absent (Glezen et al., 1986;
Nyiro et al., 2016). Moreover, vaccine trials learned that it is very hard
to boost pre-existing RSV-neutralizing antibodies in children and adults.
Maternal derived RSV-speciﬁc antibodies can provide some protec-
tion in very young infants (Glezen et al., 1986). However, these mater-
nal antibodies wane quickly after birth, which explains why 1-month-
old babies are the most likely to develop severe disease upon primary
RSV infection (Hall et al., 2009). Remarkably, these primary infections
do not elicit immunity against reinfection with RSV (Glezen et al.,
1986). This can in part be explained by the poor antibody response in
young infants as compared to older children (Murphy et al., 1986).
More recently, however, it has become clear that infants younger than
3 months are quite capable of mounting signiﬁcant RSV-neutralizing
antibodies upon RSV infection but that pre-existingmaternal antibodies
can blunt this (Shinoff et al., 2008). Profound understanding of antibody
responses upon primary RSV infection in young infants is crucial for the
development and implementation of active and passive anti-RSV vacci-
nation strategies in this age group.
In this issue of EBioMedicine, researchers from the pharmaceutical
company Daiichi Sankyo teamed up with several clinical departments
in Japan to study the age-related humoral responses in patients with
RSV who were medically attended (Jounai et al., 2017). Paired acute
and convalescent serum samples from 169 children (aged between 0om.2017.01.014.
ns).
.V. This is an open access article undand 36 months) and 23 adults (aged 24–89 years) were analyzed.
ternal RSV antibodies had become limiting. Why does the IgG3 subclass
stand out in the very young as a possible marker for a primary response
against RSV? First, RSV-speciﬁc IgG3 is virtually absent in infants youn-
ger than 4 months. Due to its shorter half-life (7 days compared to
21 days for the other IgG isotypes) IgG3 levels in both the mother and
infant decline much faster than IgG1 and IgG2 do (Hornsleth et al.,
1985). Secondly, extensive sequence analysis of human IgG transcripts
has revealed a clear hierarchy among the IgG subclasses and the extent
of afﬁnity maturation: IgG3 b IgG1 b IgG2 b IgG4 (Jackson et al., 2014).
This suggests that human B cells tend to follow a programmed sequence
of class switches from IgM to IgG3 and subsequently to IgG1, IgG2 and
IgG4. Recurrent infections with RSV would thus also gradually favor ac-
cumulation of RSV-speciﬁc IgG1, IgG2 and IgG4 over IgG3 as an individ-
ual grows up.
In the study population of Jounai et al. RSV-speciﬁc IgG1 and IgG2 re-
sponses upon medical attended RSV infection were undetectable in in-
fants younger than 4 months and could only be observed in about one
third of the infants aged between 4 and 7 months (Jounai et al., 2017).
In accordance with other reports, the infections did not result in robust
RSV-neutralizing antibody responses in these infants (Murphy et al.,
1986). In contrast, RSV infections were associated with a more than 4-
fold increase in IgG3 levels in 78.3% and 96.4% of 0–4 months old and
4–7 months old infants, respectively. RSV-speciﬁc serum IgG3 re-
sponses might thus serve as a biomarker for primary RSV infection
and associated immune responses. This might be useful to detect sub-
clinical RSV infections in young infants with considerable levels of ma-
ternal RSV antibodies, or to monitor early immune responses upon
vaccination with live attenuated RSV vaccine candidates. To further ex-
plore IgG3 response as a biomarker for RSV infections and associated
immune responses, it will be important to deﬁne the duration of such
an IgG3 response, given its short half-life. In addition, it should be inves-
tigated to what extent also subclinical RSV infections result in detect-
able IgG3 responses. Finally, RSV IgG3 responses should also be
investigated in infants less than 1 or 2months of age. If upon subclinical
RSV infections early and strong IgG3 responses occur in very young in-
fants and remain detectable for a prolonged period, this IgG3 mark
holds promise as a feasible biomarker.er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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